BusinessSummit Announces New Analysis Showing Ezutromid Significantly Reduced Muscle Inflammation in Phase 2 Clinical Trial in DMDBy Nasdaq OMXFeb 26, 2018, 12:00 PM UTC
BusinessSanthera Pharmaceuticals, Summit Therapeutics, Catabasis Pharmaceuticals and Duchenne UK to host Duchenne Muscular Dystrophy Awareness DayBy Nasdaq OMXDec 6, 2017, 7:00 AM UTC
BusinessSummit Joins cTAP in Collaborative Effort to Enhance the Development of Utrophin Modulators and Other Treatments for Duchenne Muscular DystrophyBy Nasdaq OMXSep 25, 2017, 11:00 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the First Quarter Ended 30 April 2017 and Operational ProgressBy Nasdaq OMXJun 14, 2017, 11:00 AM UTC
BusinessSummit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMDBy Nasdaq OMXMay 15, 2017, 11:01 AM UTC
BusinessSummit Completes Enrolment of PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients with DMDBy Nasdaq OMXMay 15, 2017, 11:01 AM UTC
BusinessaTyr Pharma Announces Promising Top-Line Results from Resolaris™ Phase 1b/2 Clinical Trial in Patients with Early Onset Facioscapulohumeral Muscular DystrophyBy Nasdaq OMXApr 24, 2017, 11:30 AM UTC
BusinessSummit Therapeutics Reports Financial Results for the Fourth Quarter and Fiscal Year Ended 31 January 2017 and Operational ProgressBy Nasdaq OMXMar 29, 2017, 11:02 AM UTC
